EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary Ci

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Medicines Agency (EMA) has accepted the filing of its Marketing Authorization Application (MAA) for Cinryze for acute treatment and prophylaxis against hereditary angioedema (HAE), which was submitted through the

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the launch of 'Ryze Above' (www.ryzeabove.com), an exclusive patient resources program within the company's patient support program, CINRYZESolutions®The Ryze Above program was created for HAE patients prescribed Cinryze, the

read more>>

NEW ORLEANS -- C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks and successive attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented

read more>>

CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ:DYAX) announced today that KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older is now commercially available in the United StatesHAE is a rare, genetic disorder characterized by sev

read more>>

KING OF PRUSSIA, Pa. -- CSL Behring announced today the launch of the Berinert® Expert Network (B.E.N.™), a full-service support program for healthcare providers and for hereditary angioedema (HAE) patients and their caregiversHAE is a rare and serious disorder that causes swelling in va

read more>>

CAMBRIDGE, Mass. -- A new, online resource is now available for patients with hereditary angioedema (HAE), their caregivers and physiciansThe website, www.HAEHope.com, launched today by Dyax Corp. (NASDAQ: DYAX), offers resources to help patients and their families better understand and manage HAE

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for Th

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business and present a financial update during the 28th Annual J.P. Morgan Healthcare ConferenceAs previously ann

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for Th

read more>>